|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J and Zou Z: Cancer
statistics, 2014. Cancer J Clinic. 64:9–29. 2014. View Article : Google Scholar
|
|
3
|
Burger M, Catto JW, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S and Lotan Y: Epidemiology and risk factors of urothelial
bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Imada S, Akaza H, Ami Y, Koiso K, Ideyama
Y and Takenaka T: Promoting effects and mechanisms of action of
androgen in bladder carcinogenesis in male rats. Eur Urol.
31:360–364. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boorjian S, Ugras S, Mongan NP, Gudas LJ,
You X, Tickoo SK and Scherr DS: Androgen receptor expression is
inversely correlated with pathologic tumor stage in bladder cancer.
Urology. 64:383–388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu
I, Izumi K, Chang C, Messing EM, Netto GJ and Yeh S: Expression of
androgen and oestrogen receptors and its prognostic significance in
urothelial neoplasm of the urinary bladder. BJU Int. 109:1716–1726.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kauffman EC, Robinson BD, Downes M,
Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ and Mongan NP:
Estrogen receptor-β expression and pharmacological targeting in
bladder cancer. Oncol Rep. 30:131–138. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Azevedo R, Soares J, Gaiteiro C, Peixoto
A, Lima L, Ferreira D, Relvas-Santos M, Fernandes E, Tavares A,
Cotton S, et al: Glycan affinity magnetic nanoplatforms for urinary
glycobiomarkers discovery in bladder cancer. Talanta. 184:347–355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bangma CH, Loeb S, Busstra M, Zhu X, El
Bouazzaoui S, Refos J, Van Der Keur KA, Tjin S, Franken CG, Van
Leenders GJ, et al: Outcomes of a bladder cancer screening program
using home hematuria testing and molecular markers. Eur Urol.
64:41–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Z, Li H, Chi Q, Qui Y, Li X and Xin
L: Clinical significance of serological and urological levels of
bladder cancer-specific antigen-1 (BLCA-1) in bladder cancer. Med
Sci Monit. 24:3882–3887. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gorodkiewicz E, Sankiewicz A and Laudanski
P: Surface plasmon resonance imaging biosensors for aromatase based
on a potent inhibitor and a specific antibody: Sensor development
and application for biological material. Cent Eur J Chem.
12:557–567. 2014. View Article : Google Scholar
|
|
12
|
Sankiewicz A, Guszcz T, Mena-Hortelano R,
Zukowski K and Gorodkiewicz E: Podoplanin serum and urine
concentration in transitional bladder cancer. Cancer Biomark.
16:343–350. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tokarzewicz A, Guszcz T, Onopiuk A,
Kozlowski R and Gorodkiewicz E: Utility of cystatin C as a
potential bladder tumour biomarker confirmed by surface plasmon
resonance technique. Indian J Med Res. 21:846–850. 2018.
|
|
14
|
Vrooman OP and Witjes JA: Urinary markers
in bladder cancer. Eur Urol. 53:909–916. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu S, Ye J, Wang Z, Lin SX, Lu M, Liang Y,
Zhu X, Olumi AF, Zhong W and Wu CL: Expression of aromatase in
tumor related stroma is associated with human bladder cancer
progression. Cancer Biol Ther. 19:175–180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nguyen DP, O'Malley P, Al Hussein Al
Awamlh B, Furrer MA, Mongan NP, Robinson BD, Wang GJ and Scherr DS:
Association of aromatase with bladder cancer stage and long-term
survival: New insights into the hormonal paradigm in bladder
cancer. Clin Genitourin Canc. 15:256–262.e1. 2017. View Article : Google Scholar
|
|
17
|
Carreau S, Lambard S, Delaland C,
Denis-Galeraud I, Bilinska B and Bourguiba S: Aromatase expression
and role of estrogens in male gonad: A review. Reprod Biol
Endocrin. 1:352003. View Article : Google Scholar
|
|
18
|
Miedlich SU, Karamooz N and Hammes SR:
Aromatase deficiency in a male patient-case report and review of
the literature. Bone. 93:181–186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miller WR: Aromatase inhibitors: Mechanism
of action and role in the treatment of breast cancer. Semin Oncol.
30 (4 Suppl 14):S3–S11. 2003. View Article : Google Scholar
|
|
20
|
Satoh K, Nonaka R, Ishikawa F, Ogata A and
Nagai F: In vitro screening assay for detecting aromatase activity
using rat ovarian microsomes and estrone ELISA. Biol Pharm Bull.
31:357–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gorodkiewicz E: The surface plasmon
resonance imaging sensor for papain based on immobilized cystatin.
Protein Pept Lett. 14:443–445. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gorodkiewicz E, Guszcz T,
Roszkowska-Jakimiec W and Kozlowski R: Cathepsin D serum and urine
concentration in superficial and invasive transitional bladder
cancer as determined by surface plasmon resonance imaging. Oncol
Let. 8:1323–1327. 2014. View Article : Google Scholar
|
|
23
|
Thevenot DR, Toth K, Durst RA and Wilson
GS: Electrochemical biosensors: Recommended definition and
classification. Pure Appl Chem. 71:2333–2348. 1999. View Article : Google Scholar
|
|
24
|
Laudanski P, Gorodkiewicz E, Ramotowska B,
Charkiewicz R, Kuzmicki M and Szamotowicz J: Determination of
cathepsins B, D and G concentration in eutopic proliferative
endometrium of women with endometriosis by the surface plasmon
resonance imaging (SPRI) technique. Eur J Obstet Gynecol Reprod
Bio. 169:80–83. 2013. View Article : Google Scholar
|
|
25
|
Gorodkiewicz E and Luszczyn J: Surface
plasmon resonance imaging (SPRI) sensor for cystatin determination
based on immobilized papain. Protein Pept Lett. 18:23–29. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dhefer IH, Abbas SAR and Ahmed NSH:
Polymorphism of cytochrome p450, superfamily19, polypeptide 1 gene
and related to aromatase enzyme activity in acromegaly Iraqi
patients. Asian J Pharm Clin Res. 10:228–232. 2017. View Article : Google Scholar
|
|
27
|
Meng Y, Adi D, Wu Y, Wang Y, Abudoukelimu
M, Huang D, Ma X, Liu C, Wang T, Liu F, et al: CYP19A1
polymorphisms associated with coronary artery disease and
circulating sex hormone levels in a Chinese population. Oncotarget.
8:97101–97113. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gorodkiewicz E: Surface plasmon resonance
imaging sensor for cathepsin determination based on immobilized
cystatin. Protein Pept Lett. 16:1379–1385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gorodkiewicz E, Regulska E and
Roszkowska-Jakimiec W: Determination of the active form
concentration of cathepsins D and B by SPRI biosensors. J Lab
Diagn. 46:107–109. 2010.
|
|
30
|
Grindstad T, Skjefstad K, Andersen S, Ness
N, Nordby Y, Al-Saad S, Fismen S, Donnem T, Khanehkenari MR, Busund
LT, et al: Estrogen receptors α and β and aromatase as independent
predictors for prostate cancer outcome. Sci Rep. 6:331142016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang C, Lee SO, Yeh S and Chang TM:
Androgen receptor (AR) differential roles in hormone-related tumors
including prostate, bladder, kidney, lung, breast and liver.
Oncogene. 33:3225–3234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guilherme G, Gakis G, Smith CL and Fahmy
O: Effects of androgen and estrogen receptor signaling pathways on
bladder cancer initiation and progression. Bladder Cancer.
2:127–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Castelao JE, Yuan JM, Skipper PL,
Tannenbaum SR, Dado-Dominguez M, Crowder JS, Ross RK and Yu MC:
Gender-and smoking-related bladder cancer risk. J Natl Cancer Inst.
93:538–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY,
Jian W, Sonpavde G, Ayala GE, Younes M and Lerner SP: Expression of
estrogen receptors-alpha and -beta in bladder cancer cell lines and
human bladder tumor tissue. Cancer. 106:2610–2616. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kawahara T, Ide H, Kashiwagi E,
El-Shishtawy KA, Li Y, Reis LO, Zheng Y and Miyamoto H:
Enzalutamide inhibits androgen receptor-positive bladder cancer
cell growth. Urol Oncol. 34:432.e15–e23. 2016. View Article : Google Scholar
|
|
36
|
Liu X, Cheng X, Liu X, He L, Zhang W, Wang
Y, Sun W and Ji Z: Investigation of the urinary metabolic
variations and the application in bladder cancer biomarker
discovery. Int J Cancer. 143:408–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miyamoto H, Yang Z, Chen YT, Ishiguro H,
Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, et al:
Promotion of bladder cancer development and progression by androgen
receptor signals. J Natl Cancer Inst. 99:558–568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kinoshita Y and Chen S: Induction of
aromatase (CYP19) expression in breast cancer cells through a
nongenomic action of estrogen receptor alpha. Cancer Res.
63:3546–3555. 2003.PubMed/NCBI
|
|
39
|
Kirma N, Gill K, Mandava U and Tekmal RR:
Overexpression of aromatase leads to hyperplasia and changes in the
expression of genes involved in apoptosis, cell cycle, growth, and
tumor suppressor functions in the mammary glands of transgenic
mice. Cancer Res. 61:1910–1918. 2001.PubMed/NCBI
|
|
40
|
Tekmal RR and Santen RJ: ‘Local estrogen
production: Is aromatase an oncogene?’Manni A: Contemporary
Endocrinology: Endocrinology of Breast Cancer. Humana Press;
Totowa, NY: pp. 79–89. 1999
|
